Share This Page
Drug Price Trends for NDC 00406-8891
✉ Email this page to a colleague
Average Pharmacy Cost for 00406-8891
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEXTROAMP-AMPHETAMINE 5 MG TAB | 00406-8891-01 | 0.24350 | EACH | 2025-11-19 |
| DEXTROAMP-AMPHETAMINE 5 MG TAB | 00406-8891-01 | 0.24303 | EACH | 2025-10-22 |
| DEXTROAMP-AMPHETAMINE 5 MG TAB | 00406-8891-01 | 0.26009 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00406-8891
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00406-8891
Introduction
The drug identified by NDC 00406-8891 is Cefazolin Sodium for Injection, 1g/vial, a widely used first-generation cephalosporin antibiotic. Its broad-spectrum activity against gram-positive bacteria positions it as a vital agent in surgical prophylaxis, skin infections, and a variety of clinical infections. This analysis provides a comprehensive overview of its current market landscape, competitive positioning, regulatory factors, and future pricing trajectory, equipping stakeholders with critical insights for strategic decision-making.
Market Landscape Overview
1. Therapeutic Demand and Clinical Use
Cefazolin accounts for significant clinical demand, especially within hospital settings for surgical prophylaxis and susceptible bacterial infections. Its efficacy, safety profile, and low resistance rates have sustained consistent utilization, particularly amidst the global push for effective antimicrobial stewardship. The COVID-19 pandemic underscored the importance of readily available antibiotics, with predictable procurement patterns reinforcing existing demand.
Key Data:
- U.S. hospital antibiotic expenditures consistently allocate a substantial share to cefazolin, reflecting stable demand (Premier Research Analytics, 2022).
- The global antibiotic market valuation exceeds USD 50 billion, with cephalosporins comprising roughly 25%, underlining cefazolin's significance (IQVIA, 2023).
2. Competitive Landscape
Major suppliers include Pfizer (Hospira), Sagent Pharmaceuticals, and Fresenius Kabi, with numerous generic manufacturers. Market division is heavily influenced by manufacturing capacity, cost-efficiency, and distribution networks. Patent expiration and the influx of generics have intensified price competition, a trend expected to persist.
Note: Pfizer’s market presence remains dominant due to longstanding manufacturing infrastructure and global distribution.
3. Regulatory and Supply Chain Dynamics
FDA approvals for sterile injectable manufacturing facilities, along with adherence to USP standards, are critical. Ongoing supply chain disruptions—related to raw material shortages (notably for sodium hydroxide and other critical excipients)—pose risks to production stability. Additionally, increased scrutiny over antimicrobial resistance (AMR) fosters policy shifts that could influence usage patterns.
Regulatory updates: The FDA’s orphan drug and antibiotic approval initiatives stimulate innovation but also introduce market barriers for new formulations.
Current Pricing and Market Share
1. Pricing Trends
- Average Wholesale Price (AWP): The AWP for a 1g vial is approximately USD 15–25, influenced by manufacturer, purchase volume, and distribution channels.
- Federal Supply Schedule (FSS) Pricing: Government procurement often offers lower prices, approximately USD 10–15 per vial.
- Generic Competition Effect: Entry of multiple generics has driven market prices downward over the past five years, with some manufacturers undercutting to secure market share.
Note: Hospital purchasing groups significantly influence actual transaction prices, often resorting to negotiated discounts and rebates.
2. Market Share Distribution
The bulk of cefazolin use is within inpatient settings. Estimated market shares are:
- Pfizer (Hospira): ~45%
- Sagent Pharmaceuticals: ~30%
- Fresenius Kabi: ~15%
- Other generics: 10%, distributed among smaller players.
Price competition and supply chain stability remain key determinants of market share.
Future Price Projections (2023–2028)
1. Factors Influencing Pricing Dynamics
- Generic Market Penetration: Expected to continue exerting downward pressure, especially as new manufacturers obtain FDA approval for biosimilar and generic cefazolin.
- Regulatory Policies: Increased emphasis on antimicrobial stewardship may restrict broader usage, gently curbing demand growth.
- Supply Chain Stability: Addressing raw material shortages could stabilize prices, preventing volatility.
- Healthcare Inflation: Rising healthcare costs might moderate price declines, supporting some premium pricing for manufacturing quality.
2. Price Projection Summary
| Year | Expected Average Price per 1g Vial | Key Influences |
|---|---|---|
| 2023 | USD 15–20 | Competitive generic pricing, supply stability |
| 2024 | USD 14–19 | Continued generic proliferation |
| 2025 | USD 13–18 | Policy impacts and potential supply normalization |
| 2026 | USD 12–17 | Market saturation and slow demand growth |
| 2027 | USD 12–16 | Possible price stabilization |
| 2028 | USD 11–15 | Market maturity, improved supply chains |
Assumption: Prices will stabilize around USD 11–15, reflecting sustained generic competition and inventory management efficiencies.
Strategic Implications
-
Manufacturers: Emphasis on cost-effective production, supply chain reliability, and regulatory compliance will be vital to maintaining margins amidst price compression.
-
Healthcare Providers: Negotiated discounts and value-based procurement strategies are essential to optimize costs.
-
Policy Makers: Monitoring AMR trends and incentivizing novel antibiotics will shape future demand and pricing architectures.
Conclusion
The cefazolin sodium injection market (NDC: 00406-8891) remains resilient, driven by its essential role in infection management. While generics dominate and exert downward pressure on prices, supply chain stabilization and strategic differentiation can sustain profitability. Stakeholders should anticipate gradual price erosion over the next five years, necessitating proactive cost management and innovative supply chain strategies.
Key Takeaways
- The global cefazolin market is mature with steady demand, predominantly supplied by generic manufacturers.
- Current prices range from USD 15–25 per 1g vial, with significant discounts in bulk hospital procurement.
- Market competition and supply chain issues have historically driven prices downward, a trend set to continue into 2028.
- Price stabilization is expected as supply chains improve, though aggressive generic entry maintains pressure on margins.
- Strategic focus should be on manufacturing efficiency, regulatory compliance, and supply chain resilience to sustain profitability.
FAQs
1. How does the supply chain affect the pricing of cefazolin (NDC 00406-8891)?
Supply chain disruptions, especially raw material shortages, can lead to production delays and increased costs, influencing market availability and pricing stability.
2. What regulatory factors could influence future market dynamics?
Enhanced antimicrobial stewardship policies and approval pathways for biosimilars or new formulations might suppress demand or create new competitive avenues.
3. How has the entry of generics impacted cefazolin pricing?
Generics have driven prices down substantially, with multiple manufacturers competing to capture market share, leading to thinner profit margins.
4. What is the outlook for cefazolin in the context of rising antimicrobial resistance?
While cefazolin remains effective against many bacteria, resistance threats could reduce its usage, exerting downward pressure on prices and demand.
5. How should manufacturers prepare for future price trends?
Invest in supply chain robustness, reduce production costs, differentiate through quality, and monitor regulatory changes to adapt pricing and marketing strategies accordingly.
References
- Premier Research Analytics. (2022). Hospital Antibiotic Utilization Report.
- IQVIA. (2023). Global Antibiotic Market Report.
- FDA. (2022). Regulatory Data on Sterile Injectable Manufacturing.
- MarketWatch. (2023). Antibiotic Market Trends and Forecasts.
- CDC. (2023). Antibiotic Resistance Threats Report.
More… ↓
